1911555-88-8
Chemical Structure
MPD-1
Synonym(s): Maleimide-KGDEVD-doxorubicin
- CAS No.: 1911555-88-8
- Formula:C73H90N10O29
- Molecular Weight:1571.55
InChIKey: PDOWWCUBJJKESE-BYIIEXDBSA-N
SMILES: [H][C@@]1(C[C@H](NC(OCC2=CC=C(NC([C@H](CC(O)=O)NC([C@H](C(C)C)NC([C@H](CCC(O)=O)NC([C@H](CC(O)=O)NC(CNC([C@H](CCCCNC(CCCCCN3C(C=CC3=O)=O)=O)NC(C)=O)=O)=O)=O)=O)=O)=O)C=C2)=O)[C@H](O)[C@H](C)O1)O[C@@H](C[C@](C(CO)=O)(CC4=C5O)O)C4=C(C(C(C6=C7OC)=O)=C5C(C6=CC=C7)=O)O
Biological Activity: MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8+ T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MPD-1 | MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8+ T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Byoungmo Kim, et al. Abstract 1320: Interim results of clinical trial phase 1 of pan-mKARS or PTEN loss tumor targeting peptide drug conjugates (Maleimide-KGDEVD-Doxorubicin/Exatecan). Cancer Res (2026) 86 (7_Supplement): 1320.
- [2]. Lee NK, et al. Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer. Biomaterials. 2021;277:121105. [Content Brief]
Keywords
